PT-141 (Bremelanotide) represents a paradigm shift in sexual function research. As a synthetic cyclic heptapeptide derived from Melanotan II, it activates melanocortin receptors in the central nervous system rather than working peripherally on blood flow. This fundamental difference explains why PT-141 can help subjects who don’t respond to PDE5 inhibitors like sildenafil — it addresses desire at the neurological level, not just the vascular mechanics of arousal.

The clinical evidence is substantial. Two Phase 3 RECONNECT trials demonstrated statistically significant improvements in both desire and distress scores for premenopausal women with HSDD. In men with erectile dysfunction who failed sildenafil, approximately one-third achieved adequate erection with PT-141 — with strong dose-dependent responses confirming mechanism validity. This led to FDA approval in 2019 (marketed as Vyleesi).

The melanocortin receptor system extends far beyond sexual function. MC4R is heavily involved in appetite and energy balance — defective or missing MC4R accounts for up to 6% of early-onset obesity cases. MC1R plays critical roles in immune function, with research showing anti-fungal and anti-inflammatory effects via macrophage M2 polarization. MC1R also stimulates DNA repair pathways, making it relevant to cancer prevention research — people with MC1R variants show increased risk of basal cell and squamous cell carcinomas.

Modified PT-141 derivatives have reached Phase IIb trials for hemorrhagic shock, demonstrating tissue protection and ischemia reduction during hypovolemia. For research teams investigating sexual function, obesity, immune modulation, tissue protection, or cancer biology, PT-141 provides access to a clinically validated, multi-receptor tool with FDA-approved precedent and extensive safety data.

For research use only. Not for human consumption.